SCHEMBL27747

SCHEMBL27747

CCOC(=O)C(Cc1ccc(Br)cc1)C(=O)OCC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 1/20 0.58
MAPK1 P28482 2/20 0.46
MEN1 O00255 1/20 0.46
S1PR4 O95977 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
S1PR1 P21453 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ALDH1A1 P00352 1/20 0.45
TP53 P04637 1/20 0.45
MME P08473 2/20 0.44
ACE P12821 1/20 0.44
NPY1R P25929 1/20 0.44
NPY2R P49146 1/20 0.44
LDHA P00338 1/20 0.43
HDAC1 Q13547 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2426124 0.92 MMP8 (0.54) MMP8MAPK1MEN1S1PR4LMNA
SCHEMBL1312803 0.91 MMP8 (0.62) MMP8MAPK1MEN1KMT2AALDH1A1
SCHEMBL534123 0.90 MMP8 (0.52) MMP8MAPK1MEN1S1PR4LMNA
SCHEMBL9710075 0.88 MMP8 (0.50) MMP8MAPK1MEN1S1PR4LMNA
SCHEMBL13721030 0.86 EPHX2 (0.49) MMP8MAPK1MEN1S1PR4LMNA
SCHEMBL6711568 0.85 MMP8 (0.57) MMP8MEN1LMNAMAPTKMT2A
SCHEMBL12493852 0.84 KMT2A (0.48) MMP8MAPK1MEN1S1PR4LMNA
SCHEMBL6946548 0.84 PTPRB (0.58) MMP8MEN1KMT2AALDH1A1LDHA
SCHEMBL18946161 0.84 MMP8 (0.59) MMP8ALDH1A1TP53NPY1RNPY2R
SCHEMBL5800254 0.84 MMP8 (0.55) MMP8ALDH1A1TP53NPY1RNPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2023-10-19 US disclosed
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2023-10-19 US disclosed
EP-3660004-B1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS INC (US) 2023-02-22 EP disclosed
CN-108473466-B Apelin receptor agonists and methods of use 百时美施贵宝公司 2022-04-19 CN disclosed
EP-3383860-B1 APELIN RECEPTOR AGONISTS AND METHODS OF USE BRISTOL MYERS SQUIBB CO (US) 2021-01-20 EP disclosed
CN-107267159-B Polymerizable compounds and their use in liquid crystal displays 默克专利股份有限公司 2020-12-01 CN disclosed
EP-3660004-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas Operations, Inc. (US) 2020-06-03 EP disclosed
US-10550327-B2 Polymerisable compounds and the use thereof in liquid-crystal displays MERCK PATENT GMBH (DE) 2020-02-04 US disclosed
US-10336717-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, LLC (US) 2019-07-02 US disclosed
US-10336717-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, LLC (US) 2019-07-02 US disclosed
CN-1430612-A Hete rocyclic derivatives NIPPON SHINYAKU CO LTD (JP) 2003-07-16 CN disclosed
EP-0367131-B1 Light-sensitive composition BASF AG (DE) 1995-02-22 EP disclosed
WO-1994026692-A1 BICYCLIC AMIDE DERIVATIVES AND THEIR USE AS MUSCLE RELAXANTS THE WELLCOME FOUNDATION LIMITED (GB) 1994-11-24 WO disclosed
US-5035979-A Radiation-sensitive mixture BASF AKTIENGESELLSCHAFT (DE) 1991-07-30 US disclosed
EP-0367131-A2 Light-sensitive composition BASF Aktiengesellschaft (DE) 1990-05-09 EP disclosed
EP-0195097-B1 ARACHIDONIC ACID ANALOGUES, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN MEDICINE BEECHAM GROUP PLC (GB) 1987-10-28 EP disclosed
US-4699995-A ANTIALLERGENS BEECHAM GROUP P.L.C. (GB) 1987-10-13 US disclosed
EP-0142145-B1 ARACHIDONIC ACID ANALOGUES, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN MEDICINE BEECHAM GROUP PLC (GB) 1987-03-04 EP disclosed
EP-0195097-A1 Arachidonic acid analogues, processes for their preparation and their use in medicine BEECHAM GROUP PLC (GB) 1986-09-24 EP disclosed
EP-0142145-A2 Arachidonic acid analogues, processes for their preparation and their use in medicine BEECHAM GROUP PLC (GB) 1985-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN MMP8 2801/4885MAPK1 4010/4885MEN1 1674/4885
US-10336717-B2 Inhibitors of beta-secretase BACE1, BACE2, PSEN1 MMP8 876/4885MAPK1 1949/4885MEN1 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.